Drugmaker Settles Free Speech Dispute as FDA Agrees on Label

Updated on
  • Pacira reaches deal with FDA over post-surgical drug Exparel
  • Label to say treatment isn't limited to any specific surgery

U.S. regulators have backed off an attempt to limit Pacira Pharmaceuticals Inc.’s promotion of its pain drug, striking an agreement that’s likely to fan the flames of debate over free speech and drug marketing. The company’s shares climbed as much as 20 percent.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.